Antibiotic Allergy Testing And Its Impact On Antimicrobial Stewardship In The Immunocompromised Host
Funder
National Health and Medical Research Council
Funding Amount
$124,714.00
Summary
While antibiotic allergy labels are common, the impact on immunosuppressed patients is unknown. This collaboration between Austin Health, Peter MacCallum Cancer Centre and Vanderbilt University Medical Centre (USA) will be the first Australian assessment of the impacts of antibiotic allergy labels on immunosuppressed patients. This project will provide strategies to examine the impact of and revise the antibiotic allergy labels with skin prick allergy testing and advanced immunodiagnostics.
Optimisation Of Beta-lactam Antibiotic Therapy As A Strategy To Improve Efficacy And Combat The Emergence Of Resistance
Funder
National Health and Medical Research Council
Funding Amount
$122,714.00
Summary
Antibiotic resistance is a global health priority that threatens to compromise advances in modern medicine to return practices to the pre-antibiotic era. Critically ill and patients with impaired immune function represent a vulnerable group who struggle to fight infections and who rely heavily on lifesaving antibiotics. This project aims to investigate how the efficacy of antibiotics can be optimised to prevent the emergence of resistance and preserve their effectiveness for the future.
Using Novel Causal Inference Approaches To Improve Decision-making In Infectious Diseases Epidemiology
Funder
National Health and Medical Research Council
Funding Amount
$76,365.00
Summary
Health care professionals face challenges in infectious diseases(ID) treatment and control from rapid spread of drug-resistant pathogens. Most evidence has come from randomised clinical trials (RCT); however, these are expensive to run, and their generalisability has been questioned. Causal inference methods are available to address this issue, but the uptake of these methods in ID has been limited. This study aims to utilise these epidemiological modelling to enhance the quality of future RCTs.
A Prospective, Randomised, Double-blind Trial Of Extended- Versus Bolus-infusion ?-lactam Therapy In Infective Exacerbations Of Cystic Fibrosis
Funder
National Health and Medical Research Council
Funding Amount
$148,431.00
Summary
I am an infectious diseases physician focused on the most effective way to use antibiotics to treat infections. People with cystic fibrosis often get lung infections and the bacteria that causes this, Pseudomonas aeruginosa, can be difficult to treat. I will be investigating whether infusing antibiotics over a prolonged period of time is more effective than standard therapy in treatment of Pseudomonas aeruginosa lung infections in patients with cystic fibrosis.
Advancing The Knowledge, Understanding And Management Of Respiratory Exacerbations In Children With Bronchiectasis
Funder
National Health and Medical Research Council
Funding Amount
$71,359.00
Summary
Bronchiectasis is a condition which causes significant morbidity, burden of disease and mortality in children as well as adults. Exacerbations in bronchiectasis influence the decline in lung function and quality of life for patients. Although the importance of treating exacerbations effectively is well accepted, there are no universally accepted guidelines for recognizing and managing an exacerbation of bronchiectasis in children. This study aims to fill this clinical and research gap.
Vitamin D And Genetic Susceptibility In Multiple Sclerosis
Funder
National Health and Medical Research Council
Funding Amount
$122,714.00
Summary
Vitamin D3 levels appear to predict clinical status in multiple sclerosis. The reasons for this are unclear, but may be linked to the effect of the Vitamin D Receptor (VDR) on a subset of immune cells. This project aims to identify key genes which are regulated by this receptor, by using specific gene sequencing technologies combined with knowledge of the genes which confer risk of developing MS. This may help to identify the molecular pathways underlying MS and potential treatment strategies.
Determining The Mechanisms Of Tolerance After Autologous Stem Cell Transplantation For Multiple Sclerosis – The Role Of CD39+ T Regulatory Cells
Funder
National Health and Medical Research Council
Funding Amount
$86,117.00
Summary
Autologous haematopoietic stem cell transplant offers relief for patients with aggressive forms of autoimmune diseases such as multiple sclerosis. Here, we aim to understand how this therapy relieves symptoms in multiple sclerosis patients by studying the biology of CD39+ T regulatory cells. Understanding these immune-suppressing cells can lead to the development of new transplant procedures without chemotherapy and ultimately improve transplant outcomes for autoimmune disease patients.
Environmental Risk Factors For Primary Progressive Multiple Sclerosis
Funder
National Health and Medical Research Council
Funding Amount
$86,118.00
Summary
Primary Progressive Multiple Sclerosis (PPMS) is a form of MS affecting 10% of people with the disease. PPMS has been less researched than the more common form of MS, Relapsing Remitting MS (RRMS), and unlike RRMS, there are currently no effective treatments. This project will examine whether the established risk factors for RRMS also hold for PPMS, whether the magnitude of risk associated with these factors is the same for PPMS, and whether novel risk factors for PPMS can be identified.
How Does Fampridine Affect Upper Limb Function In Multiple Sclerosis?
Funder
National Health and Medical Research Council
Funding Amount
$113,237.00
Summary
Multiple sclerosis (MS) is a common and disabling neurological disease affecting thousands of young Australians. In 2011 Fampridine received TGA approval for walking impairment in MS, but its mechanism of action is unknown and its effects on domains other than lower limb function remain untested. Our study will test whether Fampridine improves upper limb impairment in MS patients and will use electrophysiological measures of central nervous system conduction to uncover its mechanism of action.